Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Wages, Salaries and Other
Others
Ratios

Nuvation Bio (NUVB-WT) EBT (2023 - 2025)

Nuvation Bio (NUVB-WT) has disclosed EBT for 3 consecutive years, with -$36.6 million as the latest value for Q4 2025.

  • Quarterly EBT rose 25.99% to -$36.6 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$204.6 million through Dec 2025, up 63.97% year-over-year, with the annual reading at -$204.6 million for FY2025, 63.97% up from the prior year.
  • EBT for Q4 2025 was -$36.6 million at Nuvation Bio, up from -$55.8 million in the prior quarter.
  • The five-year high for EBT was -$13.8 million in Q4 2023, with the low at -$462.5 million in Q2 2024.
  • Average EBT over 3 years is -$70.7 million, with a median of -$38.9 million recorded in 2024.
  • The sharpest move saw EBT crashed 2140.76% in 2024, then surged 87.24% in 2025.
  • Over 3 years, EBT stood at -$13.8 million in 2023, then tumbled by 258.63% to -$49.4 million in 2024, then increased by 25.99% to -$36.6 million in 2025.
  • According to Business Quant data, EBT over the past three periods came in at -$36.6 million, -$55.8 million, and -$59.0 million for Q4 2025, Q3 2025, and Q2 2025 respectively.